Home / FINANCE / Markets Insider / Verastem Reports Phase 2 Long-Term Follow-Up Data For Duvelisib

Verastem Reports Phase 2 Long-Term Follow-Up Data For Duvelisib

(RTTNews) – Verastem, Inc. (VSTM) reported long-term follow-up information from a DYNAMO study, that met a primary endpoint of Overall Response Rate during a final analysis. DYNAMO is a Phase 2 clinical investigate evaluating duvelisib, a company’s investigational verbal monotherapy, twin inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with phlegmatic non-Hodgkin lymphoma whose illness is adverse to both rituximab and chemotherapy or radioimmunotherapy. With 18 months of follow-up, a information continues to be unchanging with a primary analysis.

The association pronounced a reserve form of duvelisib monotherapy stays unchanging with what has been formerly reported in phlegmatic non-Hodgkin lymphoma and other modernized hematologic malignancies.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

x

Check Also

Mexican Processed Meat Processed Cheese Market: Forecast (2017-2023)

NEW YORK, Nov. 21, 2017 /PRNewswire/ — Processed beef is beef that has been recorded ...